Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices
SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

SQI Diagnostics Inc
Bullboard Posts
User Avatar Image
(19)
•••
Post by Azzo100on May 28, 2020 9:28am
139 Views
Post# 31082083

Clinical studies approvals began in April 2020

Clinical studies approvals began in April 2020 Clinical studies in support of regulatory approvals began in April 2020 and subject enrolment is 50% complete. If successful, we anticipate the launch of two products that would not only provide financial benefits to the Company but would be critical life-saving technologies."
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities